|By PR Newswire||
|April 15, 2014 10:17 AM EDT||
CHICAGO, April 15, 2014 /PRNewswire/ -- Medac Pharma, Inc., a privately held pharmaceutical company focused on the development of new molecules and improving the effectiveness of existing medicines, announced that the U.S. Food and Drug Administration (FDA) has granted approval for the name Rasuvo™ for the company's lead compound, MPI-2505, a subcutaneous injectable methotrexate (MTX) delivered in a ready-to-use autopen.
Currently under FDA review, Rasuvo is being developed for multiple indications, including rheumatoid arthritis (RA), poly-articular-course juvenile RA and psoriasis, and is designed to improve bioavailability and overcome tolerability issues associated with today's oral MTX therapies. Medac Pharma plans to offer Rasuvo in 10 dosage strengths, ranging from 7.5 mg to 30 mg in 2.5 mg increments.
"Securing name approval for our lead compound is another important milestone as we prepare for a potential U.S. launch of Rasuvo later this year," said Ms. Terri Shoemaker, President and CEO of Medac Pharma, Inc. "With its planned 10 dosage strengths and ease of administration, Rasuvo is well-positioned to offer patients an optimal therapeutic option for managing rheumatoid arthritis and other related diseases as our product will offer the widest range of dosing options compared to other subcutaneous methotrexate therapies."
About Medac Pharma, Inc.
Medac Pharma, Inc. is the wholly-owned subsidiary of medac GmbH, a well-known and respected global pharmaceutical company that has been making scientific and therapeutic discoveries for more than 40 years.
Medac Pharma, Inc. is focused on developing therapies with the potential to make meaningful differences in patients' lives. The company's approach is to improve existing agents by enhancing the mode of delivery, addressing safety profiles and inventing ways to maximize efficacy.
For more information, please visit www.medacpharma.com.
SOURCE Medac Pharma, Inc.
WebRTC has had a real tough three or four years, and so have those working with it. Only a few short years ago, the development world were excited about WebRTC and proclaiming how awesome it was. You might have played with the technology a couple of years ago, only to find the extra infrastructure requirements were painful to implement and poorly documented. This probably left a bitter taste in your mouth, especially when things went wrong.
Jan. 17, 2017 09:15 PM EST Reads: 7,494
Jan. 17, 2017 08:45 PM EST Reads: 1,910
Jan. 17, 2017 08:00 PM EST Reads: 11,581
Jan. 17, 2017 08:00 PM EST Reads: 428
Jan. 17, 2017 06:45 PM EST Reads: 6,193
Jan. 17, 2017 05:15 PM EST Reads: 3,556
Jan. 17, 2017 04:45 PM EST Reads: 3,040
Jan. 17, 2017 04:45 PM EST Reads: 613
Jan. 17, 2017 04:45 PM EST Reads: 845
Jan. 17, 2017 04:30 PM EST Reads: 9,605
Jan. 17, 2017 04:30 PM EST Reads: 2,900
Jan. 17, 2017 04:15 PM EST Reads: 1,974
Jan. 17, 2017 03:30 PM EST Reads: 5,318
Jan. 17, 2017 02:45 PM EST Reads: 4,113
Jan. 17, 2017 02:30 PM EST Reads: 1,736